The Max Foundation (Max) and BeiGene partner to provide treatment access for Chronic Lymphocytic Leukemia (CLL) in 29 countries– a first for Max
Starting later this year, The Max Foundation, BeiGene and the BeiGene Foundation will collaborate to provide access for the treatment of adult patients with CLL in 29 low- to middle-income countries. “This collaboration marks the first-time patients with CLL will have access to treatment through Max”, said Pat Garcia-Gonzalez, CEO of Max. CLL is the most common leukemia in adults, accounting for about one-third of new cases of leukemia worldwide. Globally, there are around 40,000 deaths due to CLL per year.
Learn more
Cancer knows no boundaries
Globally, one in six deaths are related to cancer. Approximately 70% of those deaths occur in low- and middle-income countries. By bringing treatment to the people facing the greatest inequities in access, we can save tens of thousands of lives.
Our ReachYour support can save a life
Your donation is channeled directly to treatment and care for cancer patients in low-and middle-income countries, from support groups and educational materials to diagnostics and lifesaving medicine.
See how you can make a difference
Our Latest Stories & News
View All Stories
Stay Connected
Sign up to hear about our latest stories, news, and upcoming events.
